Cardurion Pharmaceuticals
Boston, MA, United States · Biotechnology, Data And Analytics, Health Care · 35 employees
Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in
Funding history
- Venture - Series Unknown — $260.4M — Jul 2024
- Series B — $260.0M — Jul 2024
- Series B — $260.0M — Jul 2024
- Venture - Series Unknown — $17.5M — Dec 2022
- Venture - Series Unknown — Undisclosed — Oct 2021
Recent signals
- Jan 08, 2025: Charlotte Newman Joins Cardurion as Chief Business Officer
- Jul 24, 2024: Raised $260.4M in Venture - Series Unknown
- Jul 16, 2024: Raised $260.0M in Series B
- Jul 16, 2024: Raised $260.0M in Series B
- Dec 30, 2022: Raised $17.5M in Venture - Series Unknown
- Oct 27, 2021: Raised funding in Venture - Series Unknown
- Nov 20, 2019: Raised $128.1M in Venture - Series Unknown
- Apr 04, 2017: Raised $15.7M in Venture - Series Unknown
See plans & pricing → Track Cardurion Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.